$246.78
1.87% day before yesterday
Nasdaq, Sep 06, 10:05 pm CET
ISIN
US02043Q1076
Symbol
ALNY
Sector
Industry

Alnylam Pharmaceuticals, Inc Stock price

$246.78
-15.78 6.01% 1M
+97.12 64.89% 6M
+55.37 28.93% YTD
+45.33 22.50% 1Y
+49.32 24.98% 3Y
+166.96 209.17% 5Y
+178.99 264.04% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-4.70 1.87%
ISIN
US02043Q1076
Symbol
ALNY
Sector
Industry

Key metrics

Market capitalization $31.68b
Enterprise Value $31.77b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 99.62
EV/Sales (TTM) EV/Sales 13.55
P/S ratio (TTM) P/S ratio 13.51
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 89.46%
Revenue (TTM) Revenue $2.34b
EBIT (operating result TTM) EBIT $102.64m
Free Cash Flow (TTM) Free Cash Flow $318.87m
Cash position $2.62b
EPS (TTM) EPS $-0.60
P/E forward negative
P/S forward 14.24
EV/Sales forward 14.28
Short interest 4.05%
Show more

Is Alnylam Pharmaceuticals, Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Alnylam Pharmaceuticals, Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Alnylam Pharmaceuticals, Inc forecast:

21x Buy
68%
9x Hold
29%
1x Sell
3%

Analyst Opinions

31 Analysts have issued a Alnylam Pharmaceuticals, Inc forecast:

Buy
68%
Hold
29%
Sell
3%

Financial data from Alnylam Pharmaceuticals, Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
2,344 2,344
89% 89%
100%
- Direct Costs 305 305
31% 31%
13%
2,040 2,040
103% 103%
87%
- Selling and Administrative Expenses 801 801
1% 1%
34%
- Research and Development Expense 1,080 1,080
10% 10%
46%
158 158
120% 120%
7%
- Depreciation and Amortization 55 55
6% 6%
2%
EBIT (Operating Income) EBIT 103 103
112% 112%
4%
Net Profit -73 -73
93% 93%
-3%

In millions USD.

Don't miss a Thing! We will send you all news about Alnylam Pharmaceuticals, Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alnylam Pharmaceuticals, Inc Stock News

Neutral
Business Wire
8 days ago
DALLAS--(BUSINESS WIRE)--Steward Health Care (“Steward”), the country's largest physician-led, minority-owned, integrated health care system, announced today it has reached an agreement in principle with its landlord, Medical Properties Trust, Inc. (“MPT”), supported by the “FILO” secured lenders under its funded debt and the official committee of unsecured creditors. Following Bankruptcy Court...
Positive
Seeking Alpha
8 days ago
Alnylam's stock surged due to positive HELIOS-B trial results, but lacked additional upside today after the company presented the data at the ESC congress. Amvuttra shows competitive efficacy and safety in ATTR amyloidosis, with the potential to rival Pfizer's Vyndaqel and other emerging treatments. I believe HELIOS-B's success is priced in at current levels and that further upside is limited i...
Neutral
Business Wire
8 days ago
BAKERSFIELD, Calif.--(BUSINESS WIRE)--The Kern Subbasin Groundwater Sustainability Agencies (GSAs) have responded to a draft report from the California State Water Resources Control Board (SWRCB). The draft report finds the Kern subbasin's Groundwater Sustainability Plan (GSP) to be inadequate and recommends that the subbasin be placed on probation. The GSAs' response was submitted during publi...
More Alnylam Pharmaceuticals, Inc News

Company Profile

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Head office United States
CEO Yvonne Greenstreet
Employees 2,100
Founded 2002
Website www.alnylam.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today